Several important biomarkers have been uncovered in endocrine-resistant HR+/HER2- breast cancer, leading to new and emerging treatment options for these patients. Test your knowledge of relevant biomarker assessment and agents that combat endocrine resistance in HR+/HER2- breast cancer with this bite-sized Booster Quiz. Receive immediate expert feedback and, following the quiz, download a summary of key supporting evidence.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/accelerating-evidence-practice-new-treatment-advances-overcome-endocrine
- Start Date: 2024-06-28 05:00:00
- End Date: 2024-06-28 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest